Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » News » VHL Awareness Event at Parliament House Highlights Urgent Need for Belzutifan Approval

VHL Awareness Event at Parliament House Highlights Urgent Need for Belzutifan Approval

  • July 8, 2024

In a powerful demonstration of solidarity and urgency, the Von-Hippel-Lindau (VHL) Awareness event held at Parliament House on 4 July 2024 brought together VHL patients, carers, and policymakers to advocate for the fast-tracked approval of Belzutifan, the only medicine showing significant promise in treating Von Hippel Lindau (VHL) disease.

The event, organised by NeuroEndocrine Cancer Australia, followed the overwhelming support evidenced by the House of Representatives Petition, which gathered 17,803 signatures. Invitations were extended to Members of Parliament from across Australia, VHL patients, and their carers. The event highlighted the desperate need for Belzutifan, a medication that has shown remarkable success in real-world evidence and clinical trials in shrinking tumours, halting their growth, and in some cases, making them disappear entirely, thus eliminating the need for future surgeries.

Watch recording of this event here.

A Groundbreaking Treatment

Ryan, a VHL patient, expressed the burden many feel:

"I feel like I am a burden on the health care system"
Ryan
VHL Patient

Amelia, another patient, asked, 

"Why do we have to wait? I have children. I have cost the health system a fortune."
Amelia
VHL Patient

These personal stories underscored the urgency of making Belzutifan available through the Pharmaceutical Benefits Scheme (PBS). The inclusion of Belzutifan on the PBS would bring the cost down from $12,000 per month to a more affordable $7.70 for those patients with a healthcare card.

The real sense of hope and urgency of PBS approval around this ground breaking treatment was re-iterated by two of Australia’s leading experts in VHL.

Dr. Minmin Li, captured the hope that Belzutifan represents for VHL patients, “For the first time ever, we have disease control.”

“Not all VHL patients will qualify for Belzutifan – we are talking about possibly 300 people.
Prof Kathy Tuckers

Significant Attendance and Support

With over 60 people registered and many more attending, including Members of Parliament, Senior Advisors, and the CEO of Medicines Australia, the event showcased widespread support. Hon. Zali Steggall OAM MP hosted the event, with Hon. Ged Kearney MP, Assistant Minister for Health, officially opening it, and Michael Usher, the event’s ambassador, facilitating the panel discussion.

Lana, a VHL patient in attendance, shared her experience with MPs and MedNews, highlighting the impact the medication would have on her life.

"Belzutifan can’t give me back what I’ve lost, but it can stop me losing more and, most importantly, give the next generation of VHL patients a brighter and better life. That’s really who this medication is for”.
Lana
VHL Patient

Lana added,

“It (VHL) is a troll which attacks me again and again – there is never really a break because even when I don’t have imminent surgery on the horizon, I am dealing with deficits from previous ones and the underlying anxiety that comes from having an uncertain future.”

A Call to Action

We urge the Government to implement Recommendation 10 from the recent Senate Inquiry: 3.134. The committee recommends that the Australian Government utilise the Health Technology Assessment Policy and Methods Review to provide Australian rare and less common cancer patients with timely and affordable access to novel medicines. 

"It is unfair that some people are living overseas to access Belzutifan while patients in Australia cannot. Everyone should have access."
Simone Leyden
Co-founder of NECA and VHL sibling

Henry Pike MP emphasized the importance of grassroots advocacy, urging patients to contact their local MPs to influence an outcome.

A Plea for Equitable Access

Meredith Cummins, CEO of NeuroEndocrine Cancer Australia, stressed,

"VHL patients do not have equitable or affordable access to medications such as Belzutifan to control their tumours. Without this medication, their lives are plagued with ongoing surgery, reduced quality of life, reduced hope, and the opportunity to have a life with their family. Time is running out for many."
Meredith Cummins
CEO, NECA

“Patients should not have to choose between available treatment or suffering without care because that treatment is completely cost prohibitive,” urged Zali Steggall, MP.

“I urge the government to act on the recommendations from the recent Inquiry into Rare Cancers, including Neuroendocrine Cancer, and list Belzutifan on the PBS.”

As the parliamentary bells rang, calling MPs back to their sessions, the stories of Ryan, Amelia, Chris, and others echoed through the halls, a compelling reminder that the approval of Belzutifan is not just a matter of policy but a matter of life and hope for many Australian families.

This event was kindly covered by the following media. The Nightly, ABC Radio, MedNews and BioPharma Dispatch

Share this post

Recent posts

VHL Awareness Month 2025

May 6, 2025

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

May 5, 2025

Help Us Grow: Connect NECA with Corporate Partners to Make a Lasting Impact

April 29, 2025

Neuroendocrine Cancer Awareness Daily Mail 5 April 2025

April 5, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousNeuroEndocrine Cancer Australia (NECA) receives inaugural Government Grant for Specialist Support Services.
NextTelehealth Support Team GrowsNext

Related Posts

VHL Awareness Month 2025

May is internationally recognised as Von Hippel-Lindau (VHL) Awareness Month—a time to highlight this rare genetic, and in some case not genetic, condition and the

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

NeuroEndocrine Cancer Australia (NECA) is proud to recognise the advocacy efforts of NET patient Chris Geljon, who has taken the time to raise awareness of

Help Us Grow: Connect NECA with Corporate Partners to Make a Lasting Impact

NeuroEndocrine Cancer Australia (NECA) is proud to be the voice for thousands of Australians living with Neuroendocrine Cancer (NETs). But to do more — reach

Neuroendocrine Cancer Awareness Daily Mail 5 April 2025

Jo O’Halloran was in her early fifties when the symptoms she and her friends had heard so much about started to appear. ‘I was always

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin